J nos pog ny pharmacist phd consultant to who shanghai 01 march 2005 e mail pogany@axelero hu l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 33

Workshop on Quality Assurance and GMP of Multisource HIV /AIDS medicines PowerPoint PPT Presentation


  • 126 Views
  • Uploaded on
  • Presentation posted in: General

János Pogány, pharmacist, PhD, consultant to WHO Shanghai, 01 March 2005 E-mail: [email protected] Workshop on Quality Assurance and GMP of Multisource HIV /AIDS medicines. Stability Studies A brief overview. Subjects for Discussion. Definitions

Download Presentation

Workshop on Quality Assurance and GMP of Multisource HIV /AIDS medicines

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


J nos pog ny pharmacist phd consultant to who shanghai 01 march 2005 e mail pogany@axelero hu l.jpg

János Pogány, pharmacist, PhD,

consultant to WHO

Shanghai, 01 March 2005

E-mail: [email protected]

Workshop on Quality Assurance and GMP of Multisource HIV/AIDSmedicines

Stability Studies

A brief overview

Dr. Pogány - WHO, Shanghai


Subjects for discussion l.jpg

Subjects for Discussion

  • Definitions

  • Planning stability studies and reporting results

  • Stability testing of APIs

  • Stability testing of FPPs

  • Evaluation of stability results

  • Conclusions

Dr. Pogány - WHO, Shanghai


Definitions l.jpg

DEFINITIONS

Re-test date

The date after which samples of the API should be examined to ensure that the materialis still in compliance with the specification and thussuitable for use in the manufacture of a given FPP.

Re-test period

The period of time during which the API is expected to remain within its specification and, therefore, can be used in the manufacture of a given FPP, provided that the API has been stored under the defined conditions. After this period, a batch of API destined for use in the manufacture of a FPP should be re-tested for compliance with the specification and then used immediately. A batch of API can be re-tested multiple times and a different portion of the batch used after each re-test, as long as it continues to comply with the specification.

Dr. Pogány - WHO, Shanghai


Definitions4 l.jpg

DEFINITIONS

Expiration date (also referred to as expiry date)

The date placed on the container label of an API or a FPP designating the time prior to which a batchof the API/FPP is expected to remain within the approved shelf-life specification if stored underdefined conditions, and after which it must not be used.

Shelf life (expiration dating period,conformance period)

The time period during which an API or a FPP is expected to remain within the approved shelf-lifespecification, provided that it is stored under the conditions defined on the container label.

Dr. Pogány - WHO, Shanghai


Planning and reporting l.jpg

Planning and Reporting

Stability Studies


Stability protocol and report l.jpg

Stability Protocol and Report

  • Batches tested

  • General information

  • Container/closure system

  • Literature and supporting data

  • Stability-indicating analytical methods

  • Testing plan

  • Test parameters

  • Test results

  • Other requirements (post-approval commitments)

  • Conclusions

Dr. Pogány - WHO, Shanghai


Stability protocol and report7 l.jpg

Stability Protocol and Report

  • The design of the formal stability studies for the FPPshould be based on knowledge of the behaviour and properties of the API and the FPP.High risk and low risk ARVs.

  • The methodology used during stability studiesshould be described. The test procedures applied to the stability tests on the API/FPPshould be validated or verified, and the accuracy as well as the precision (standard deviations) should be recorded.

Dr. Pogány - WHO, Shanghai


Data of api stability batches l.jpg

Data of API Stability Batches

The batches should be representative of the manufacturing process and should be manufactured from different batches of key intermediates.

Dr. Pogány - WHO, Shanghai


Data of capsule tablet stability batches l.jpg

Data of Capsule/Tablet Stability Batches

The batches should be representative of the manufacturing process and should be manufactured from different batches of APIs.

Dr. Pogány - WHO, Shanghai


2 7 stability testing who prequalification project l.jpg

2.7 Stability TestingWHO Prequalification Project

API


Stress testing forced degradation l.jpg

Stress testing (forced degradation)

Dr. Pogány - WHO, Shanghai


F orced degradation tests l.jpg

Forced degradation tests

  • Tovalidate the stability indicating power of the analytical procedures.

  • To identify stability-affecting factorssuch as ambient temperature, humidity and light and to select packing materials, which protect the FPP against such effects.

  • To identify potential degradants of the API and assess if they can be formed during manufacture or storage of the FPP.

  • No standard method, 10-30% degradation, stress factors, conditions and time

  • Solid state degradation (supporting information)

Dr. Pogány - WHO, Shanghai


Formal regulatory stability testing l.jpg

Formal (Regulatory) Stability Testing

Dr. Pogány - WHO, Shanghai


Stability room l.jpg

A special cabinet for each condition

Design, construction, qualification, monitoring

Costs of operation including R + D failures

Time

Do we need new standard conditions?

Stability Room

Dr. Pogány - WHO, Shanghai


Stability results l.jpg

Stability results

  • A storage statement should be proposed for the labeling (if applicable), which should be based on the stability evaluation of the API.

  • A re-test period should be derived from the stability information, and the approved retest date should be displayed on the container label.

  • An API is considered as stable if it is within the defined/regulatory specifications when stored at 30±2oC and 65±5% RH for 2 years and at 40±2oC and 75±5%RH for 6 months.

Dr. Pogány - WHO, Shanghai


3 11 stability testing who prequalification project l.jpg

3.11Stability testing WHO Prequalification Project

FPP


Potential instability issues of fpps l.jpg

Potential Instability Issues of FPPs

  • Loss/increase in concentration of API

  • Formation of (toxic)degradation products

  • Modification of anyattribute of functional relevance

  • Alteration of dissolution time/profile or bioavailability

  • Decline of microbiological status

  • Loss of package integrity

  • Reduction of label quality

  • Loss of pharmaceutical elegance and patient acceptability

Dr. Pogány - WHO, Shanghai


Increase in concentration of api l.jpg

Increase in concentration of API

During stability studies of Artesunate, the assay results were increasing. The hydrolysis may yield artenimol and succinic acid. The latter can justify the increase in assay. The assay method is „stability indicating” but not specific.

+

Dr. Pogány - WHO, Shanghai


Stability indicating quality parameters l.jpg

Stability-indicating quality parameters

Stability studies should include testing of those attributes of the FPP that are susceptible to change during storage and are likely to influence quality, safety and/or efficacy.For instance, in case of tablets:

♦appearance ♦ hardness

♦friability♦moisture content

♦dissolution time♦degradants

♦assay ♦microbial purity

Dr. Pogány - WHO, Shanghai


Selection of batches l.jpg

Selection of Batches

  • At the time of submission data from stability studies should be provided for batches of the same formulationand dosage formin the container closure system proposed for marketing.

  • Stability data on three primary batches are to be provided. The composition, batch size, batch number and manufacturing date of each of the stability batches should be documented and the certificate of analysis at batch release should be attached.

  • Where possible, batches of the FPP should be manufactured by using different batches of the API.

Dr. Pogány - WHO, Shanghai


Evaluation variation trend l.jpg

Evaluation – Variation, Trend

  • A systematic approach should be adopted in the presentation and evaluation of the stability information.

  • Where the data show so little degradation and so little variability that it is apparent from looking at the data that the requested shelf life will be granted, it is normally unnecessary to go through the formal statistical analysis; providing a justification for the omission should be sufficient.

  • An approach for analysing data on a quantitative attribute that is expected to change with time is to determine the time at which the 95% one-sided confidence limit for the mean curve intersects the (lower) acceptance criterion (95% assay).

Dr. Pogány - WHO, Shanghai


S ignificant c hange of fpps l.jpg

Significant Change of FPPs

  • A 5% change in assay from its initial value.

  • Any degradation product exceeding its acceptance criterion.

  • Failure to meet the acceptance criteria for appearance, physical attributes, and functionality test (e.g., colour, phase separation, hardness).

  • As appropriate for the dosage form, e.g., failure to meet the acceptance criteria for dissolution for 12 dosage units.

Dr. Pogány - WHO, Shanghai


Evaluation best case l.jpg

Evaluation – Best Case

  • Tabulate and plot stability data on all attributes at all storage conditions and evaluate each attribute separately.

  • No significant change at accelerated conditions within six (6) months.

  • Long-term data show little orno variabilityand little or no change over time.

Dr. Pogány - WHO, Shanghai


Evaluation best case24 l.jpg

Evaluation – Best Case

  • Accelerated data show little or no variability and little or no change over time.

  • Statistical analysis is normally unnecessary.

  • Proposed retest period or shelf life = double of period covered by long-tem data (X) but NMT X + 12 months

  • A retest period or shelf life granted on the basis of extrapolation should always be verified by additional long-term stability data

Dr. Pogány - WHO, Shanghai


Ich q1e evaluation f or stability data l.jpg

ICH-Q1E Evaluation for Stability Data

Dr. Pogány - WHO, Shanghai


Evaluation change with time l.jpg

Evaluation – Change with Time

  • The hypothetical figure in the former slide illustrates that the extrapolated shelf life is 29months (25oC/60%RH) and there is only a 5% chance that this estimate will be high. Such a plot covers assay values from 105% down to 95%.

  • The majority of degradation processes results in an essentially linear line in this range of the label claim thus the method is generally applicable for the estimation of the expiry date at the studied storage conditions.

Dr. Pogány - WHO, Shanghai


Carstensen j t drug stability l.jpg

Carstensen, J.T. – Drug stability

Dr. Pogány - WHO, Shanghai


Evaluation change with time28 l.jpg

Evaluation – Change with Time*

The hypothetical figure in the former slide illustrates that the shelf life is 24 months (at a given temperature). There is a 5% chance that this estimate will be high.Such a plot covers potency values from 100% down to 90%.

*DRUG STABILITY — Principles and Practices

Edited by Jens T. Carstensen and C. T. Rhodes

Third edition, revised and expanded (2000)

Marcel Dekker, Inc., 270 Madison Avenue, New York,

Dr. Pogány - WHO, Shanghai


Ich q1e evaluation f or stability data29 l.jpg

ICH-Q1E Evaluation for Stability Data

Dr. Pogány - WHO, Shanghai


Evaluation change with time30 l.jpg

Evaluation – Change with Time

  • The hypothetical figuresin the former slides illustrate that the shelf life is 31-32months (

  • (25oC/60%RH) and there is only a 5% chance that this estimate will be high. Such a plot covers degradant values from 0.6% up to 1.4%.

  • For FPPs in semipermeable containers, loss of vehicle can result in an increase in the API concentration. In such cases, the point where the upper 95% confidence bound intersects the 105% assay value will define the conformance period.

Dr. Pogány - WHO, Shanghai


Additional or new stability data l.jpg

Additional or New Stability Data

  • Modifications affecting one or more steps of thesame route ofsynthesis of an API

  • Change in the route of synthesis of an API

  • Change in composition of the FPP

  • Change in immediate packaging of the FPP

Dr. Pogány - WHO, Shanghai


Main points again l.jpg

Main points again

  • Stability studies should be planned on the basis of pharmaceutical R+D and regulatory requirements.

  • Forced degradation studies reveal the intrinsic chemical properties of the API, while formal stability studies establish the retest date.

  • The shelf life (expiry date) of FPPs is derived from formal stability studies.

  • Variability and time trends of stability data must beevaluated by the manufacturer in order to propose a retest date or expiry date.

Dr. Pogány - WHO, Shanghai


Thank you l.jpg

THANK YOU

谢谢!

Dr. Pogány - WHO, Shanghai


  • Login